Cormorant Pharmaceuticals

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals

Tuesday, July 5, 2016

Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant Pharmaceuticals, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The acquisition gives Bristol-Myers Squibb full rights to Cormorant’s HuMax-IL8 antibody program and the lead candidate HuMax-IL8, a phase I/II monoclonal antibody targeted against interleukin-8 (IL-8) that represents a potentially complementary immuno-oncology mechanism of action to T-cell directed antibodies and co-stimulatory molecules.

[Read More]